Check for updates

OPEN ACCESS

EDITED BY Mladen-Roko Rasin, The State University of New Jersey, United States

REVIEWED BY Rincic Martina, University of Zagreb, Croatia Stewart Alan Anderson, University of Pennsylvania, United States

*CORRESPONDENCE Wieland B. Huttner, Muttner@mpi-cbg.de

RECEIVED 16 July 2024 ACCEPTED 08 November 2024 PUBLISHED 27 November 2024

CITATION

Huttner WB (2024) Human-specific gene *ARHGAP11B*—potentially an additional tool in the treatment of neurodegenerative diseases? *Front. Mol. Med.* 4:1465647. doi: 10.3389/fmmed.2024.1465647

COPYRIGHT

© 2024 Huttner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Human-specific gene ARHGAP11B—potentially an additional tool in the treatment of neurodegenerative diseases?

Wieland B. Huttner*

Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany

KEYWORDS

ARHGAP11B, basal progenitors, human-specific gene, metabolism, neural stem cells

Introduction

One strategy in the treatment of neurodegenerative diseases has been to replenish lost cells, notably neurons. Approaches taken to this end have included the following: first, to either activate neural stem cells that endogenously exist in certain neurogenic niches of the adult human brain such that new neurons are being generated where needed [for recent reviews, see Temple (2023); Vassal et al. (2024); Velikic et al. (2024)]; second, to graft exogenous neural stem cells and/or exogenously generated neurons into the affected brain region, often by making use of patient-derived induced pluripotent stem cells (iPSCs) to obtain the former cells [for recent reviews, see Lee et al. (2024); Temple (2023); Vadodaria et al. (2020)].

In this brief Opinion Article, I would like to draw attention to the human-specific gene *ARHGAP11B*, which exhibits properties that could potentially be beneficial in the treatment of neurodegenerative diseases.

Features of ARHGAP11B

ARHGAP11B is typically referred to as a human-specific gene. This statement is correct in terms of extant species, as *ARHGAP11B* does not occur in any other primate or mammal. However, from an evolutionary point of view, *ARHGAP11B* is actually a hominin-specific gene, as it has been shown to have occurred in Neanderthals and Denisovans, and in light of its origin, ~5 mya, it likely occurred in other members of the *Homo* lineage [for a recent review, see Huttner et al. (2024)].

Besides the function of the ARHGAP11B protein, that is, to stimulate glutaminolysis in mitochondria (Namba et al., 2020; see *Discussion*), a key feature of the *ARHGAP11B* gene as a potential additional tool in the treatment of neurodegenerative diseases pertains to the cell types in which this gene is expressed. Thus, in the fetal human neocortex, the cells exhibiting the highest level of *ARHGAP11B* expression are the neural stem and progenitor cells. Specifically, during neurogenesis, *ARHGAP11B* is expressed in both the apical progenitors residing in the ventricular zone and the basal progenitors residing in the subventricular zone, notably apical radial glia and basal (or outer) radial glia, respectively (Florio et al., 2015). Such expression can be seen as a strategic advantage if one intends to use cortical stem and progenitor cells for therapeutic approaches in neurodegenerative diseases that aim to achieve cell replacement.

Indeed, and of potential clinical relevance, the expression of *ARHGAP11B* in various animal model systems *in vivo* has been shown to amplify basal progenitors, the progenitor cells that

generate cortical neurons (Florio et al., 2015; Kalebic et al., 2018; Heide et al., 2020; Xing et al., 2021). Moreover, the effects of *ARHGAP11B* on basal progenitors result in an increase in cortical neuron production *in vivo* (Florio et al., 2015; Kalebic et al., 2018; Heide et al., 2020; Xing et al., 2021). Of note, *ARHGAP11B* expression *in vivo* increases the so-called upper-layer neurons, the class of cortical neurons implicated in higher cognitive abilities (Kalebic et al., 2018; Heide et al., 2020; Xing et al., 2021). The amplification of basal progenitors *in vivo* by *ARHGAP11B* is based on the ability of this gene to induce basal progenitor self-renewal (Florio et al., 2015; Kalebic et al., 2018; Heide et al., 2020). Hence, *ARHGAP11B* fulfills a key criterion for its potential therapeutic application in neuron replenishment strategies for the treatment of neurodegenerative diseases—the ability to induce *in vivo* the self-renewal of those progenitor cells that generate cortical neurons.

Potential approaches to using ARHGAP11B as an additional tool in the treatment of neurodegenerative diseases

To explore the potential use of *ARHGAP11B* as an additional tool in the treatment of neurodegenerative diseases approaches to be considered include the following. First, one could aim at targeting the endogenous neural stem cells in the adult human brain with an appropriate *ARHGAP11B* expression vector. Neural stem cells and/or neurogenesis in the adult human brain have so far been detected in the hippocampus [for a review, see Kempermann et al. (2015)], the amygdala (Roeder et al., 2022), and the subventricular zone of the lateral ventricles [for a recent summary, see Baig et al. (2024)]. An appropriate *ARHGAP11B* expression vector should feature an inducible on–off expression system to first amplify the respective neural stem cells by switching on *ARHGAP11B* expression, to allow them to generate neurons.

A second line of approach could make use of patient-derived iPSCs that are first converted to neural stem cells, into which an appropriate *ARHGAP11B* expression system is then introduced. Such neural stem cells with the capacity to allow an inducible expression of *ARHGAP11B* could then be administered into the brain region of interest, followed by local neural stem cell amplification and then local neurogenesis, as mentioned above.

Discussion

Should the transient (i.e., inducible) expression of *ARHGAP11B* indeed lead to local neural stem cell amplification and consequently

References

Baig, S., Nadaf, J., Allache, R., LE, P. U., Luo, M., Djedid, A., et al. (2024). Identity and nature of neural stem cells in the adult human subventricular zone. *iScience* 27, 109342. doi:10.1016/j.isci.2024.109342

Florio, M., Albert, M., Taverna, E., Namba, T., Brandl, H., Lewitus, E., et al. (2015). Human-specific gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion. *Science* 347, 1465–1470. doi:10.1126/science.aaa1975

Heide, M., Haffner, C., Murayama, A., Kurotaki, Y., Shinohara, H., Okano, H., et al. (2020). Human-specific ARHGAP11B increases size and folding of primate neocortex in the fetal marmoset. *Science* 369, 546–550. doi:10.1126/science.abb2401

to local neuronal replenishment, a key future task of this approach will be to determine whether the newly generated neurons are able to functionally compensate for the lost neurons. If so, it may be forward-looking to consider the mechanism underlying the ability of *ARHGAP11B* to amplify neural stem cells. The ARHGAP11B protein has been shown to be imported into the matrix of mitochondria in the cells expressing this gene, where ARHGAP11B stimulates the metabolic pathway called glutaminolysis (Namba et al., 2020). In light of the emerging concept that changes in metabolism exert a crucial impact on the behavior of neural stem cells (Namba et al., 2021), targeting specific metabolic pathways may aid future therapeutic endeavors in the treatment of neurodegenerative diseases.

Author contributions

WH: writing-original draft and writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The author was supported by the Max Planck Society.

Acknowledgments

The author thanks Takashi Namba for his comments on this manuscript.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Huttner, W. B., Heide, M., Mora-Bermúdez, F., and Namba, T. (2024). Neocortical neurogenesis in development and evolution—human-specific features. *J. Comp. Neurol.* 532, e25576. doi:10.1002/cne.25576

Kalebic, N., Gilardi, C., Albert, M., Namba, T., Long, K. R., Kostic, M., et al. (2018). Human-specific ARHGAP11B induces hallmarks of neocortical expansion in developing ferret neocortex. *eLife* 7, e41241. doi:10.7554/eLife.41241

Kempermann, G., Song, H., and Gage, F. H. (2015). Neurogenesis in the adult hippocampus. *Cold Spring Harb. Perspect. Biol.* 7, a018812. doi:10.1101/cshperspect. a018812

Lee, D.-H., Lee, E. C., Lee, J. Y., Lee, M. R., Shim, J.-W., and Oh, J. S. (2024). Neuronal cell differentiation of iPSCs for the clinical treatment of neurological diseases. *Biomedicines* 12, 1350. doi:10.3390/biomedicines12061350

Namba, T., Doczi, J., Pinson, A., Xing, L., Kalebic, N., Wilsch-Bräuninger, M., et al. (2020). Human-specific ARHGAP11B acts in mitochondria to expand neocortical progenitors by glutaminolysis. *Neuron* 105, 867–881. doi:10.1016/j.neuron.2019.11.027

Namba, T., Nardelli, J., Gressens, P., and Huttner, W. B. (2021). Metabolic regulation of neocortical expansion in development and evolution. *Neuron* 109, 408–419. doi:10. 1016/j.neuron.2020.11.014

Roeder, S. S., Burkardt, P., Rost, F., Rode, J., Brusch, L., Coras, R., et al. (2022). Evidence for postnatal neurogenesis in the human amygdala. *Commun. Biol.* 5, 366. doi:10.1038/s42003-022-03299-8

Temple, S. (2023). Advancing cell therapy for neurodegenerative diseases. *Cell Stem Cell* 30, 512–529. doi:10.1016/j.stem.2023.03.017

Vadodaria, K. C., Jones, J. R., Linker, S., and Gage, F. H. (2020). Modeling brain disorders using induced pluripotent stem cells. *Cold Spring Harb. Perspect. Biol.* 12, a035659. doi:10.1101/cshperspect.a035659

Vassal, M., Martins, F., Monteiro, B., Tambaro, S., Martinez-Murillo, R., and Rebelo, S. (2024). Emerging pro-neurogenic therapeutic strategies for neurodegenerative diseases: a review of pre-clinical and clinical research. *Mol. Neurobiol.* doi:10.1007/s12035-024-04246-w

Velikic, G., Maric, D. M., Maric, D. L., Supic, G., Puletic, M., Dulic, O., et al. (2024). Harnessing the stem cell niche in regenerative medicine: innovative avenue to combat neurodegenerative diseases. *Int. J. Mol. Sci.* 25, 993. doi:10.3390/ijms25020993

Xing, L., Kubik-Zahorodna, A., Namba, T., Pinson, A., Florio, M., Prochazka, J., et al. (2021). Expression of human-specific ARHGAP11B in mice leads to neocortex expansion and increased memory flexibility. *EMBO J.* 40, e107093. doi:10.15252/embj.2020107093